Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity.
Anti-digoxin antibody fragments (ADAF, 80 mg) were infused intravenously to successfully treat severe digoxin toxicity in an 82 year old woman. During treatment, total and free digoxin were determined using an Abbot TDX analyser and an ultrafiltration technique. ADAF were measured by an enzyme-linked immunosorbent assay. By 1 h after ADAF, total serum digoxin concentrations had risen 12-fold from a pretreatment level of 15.4 nmol l-1 but free digoxin fell from 10 to 0.1 nmol l-1, indicating greater than 99.9% digoxin binding to ADAF. However, the low free levels had rebounded to 7.7 nmol l-1 by 12 h, but despite this rise the patient's condition had improved. A serum ADAF/digoxin molar ratio of around five was associated with the low concentration of free digoxin at 1 h, while at later times with ratios roughly between 3 and 4, the free digoxin concentrations ranged between 2.0 and 7.7 nmol l-1. ADAF were mainly confined to the plasma during the first hour, but subsequently distributed into an apparent volume of 193 ml kg-1. The elimination half-lives of ADAF and total digoxin were 96 and 55 h, respectively. More than 50% of the estimated digoxin load had been excreted in the urine by 5 days; for ADAF the equivalent figure was only about 3%. Renal and/or bacterial degradation may have contributed to the low detection of urinary ADAF.
Sinclair
A J
AJ
Department of Geriatric Medicine, University of Birmingham, Selly Oak Hospital.
Hewick
D S
DS
Johnston
P C
PC
Stevenson
I H
IH
Lemon
M
M
D000368:Aged; D000369:Aged, 80 and over; D004077:Digoxin / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006207:Half-Life; D006801:Humans; D007128:Immunoglobulin Fragments / Q000032:analysis*; D011188:Potassium / Q000097:blood
D007128:Immunoglobulin Fragments; D004077:Digoxin; D011188:Potassium